Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2016

Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2016
Published Jun 22, 2016
73 pages — Published Jun 22, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2016, provides an overview of the Hyperphosphatemia In Chronic Kidney Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperphosphatemia In Chronic Kidney Disease and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hyperphosphatemia In Chronic Kidney Disease
- The report reviews pipeline therapeutics for Hyperphosphatemia In Chronic Kidney Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hyperphosphatemia In Chronic Kidney Disease therapeutics and enlists all their major and minor projects
- The report assesses Hyperphosphatemia In Chronic Kidney Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hyperphosphatemia In Chronic Kidney Disease

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies <

  
Source:
Document ID
GMDHC8189IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Hyperphosphatemia In Chronic Kidney Disease Overview71
Therapeutics Development82
  Pipeline Products for Hyperphosphatemia In Chronic Kidney Disease Overview81
  Pipeline Products for Hyperphosphatemia In Chronic Kidney Disease Comparative Analysis91
Hyperphosphatemia In Chronic Kidney Disease Therapeutics under Development by Companies101
Hyperphosphatemia In Chronic Kidney Disease Therapeutics under Investigation by Universities/Institutes111
Hyperphosphatemia In Chronic Kidney Disease Pipeline Products Glance123
  Late Stage Products121
  Clinical Stage Products131
  Early Stage Products141
Hyperphosphatemia In Chronic Kidney Disease Products under Development by Companies151
Hyperphosphatemia In Chronic Kidney Disease Products under Investigation by Universities/Institutes161
Hyperphosphatemia In Chronic Kidney Disease Companies Involved in Therapeutics Development179
  3SBio Inc.171
  Ardelyx, Inc.181
  Daiichi Sankyo Company, Limited191
  Medice Arzneimittel Putter GmbH &Co. KG201
  OPKO Health, Inc.211
  Panion &Bf Biotech Inc221
  Shield Therapeutics Plc231
  Spectrum Pharmaceuticals, Inc.241
  Toray Industries, Inc.251
Hyperphosphatemia In Chronic Kidney Disease Therapeutics Assessment268
  Assessment by Monotherapy Products261
  Assessment by Target272
  Assessment by Mechanism of Action292
  Assessment by Route of Administration311
  Assessment by Molecule Type322
Drug Profiles3425
  DS-2330 Drug Profile341
  fermagate Drug Profile351
  ferric citrate Drug Profile368
  JPH-101 Drug Profile441
  niacinamide Drug Profile451
  PDX-004 Drug Profile461
  PT-20 Drug Profile471
  RDX-002 Drug Profile481
  sevelamer carbonate Drug Profile491
  Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia In CKD Drug Profile501
  Small Molecules to Target Phosphate for Hyperphosphatemia Drug Profile511
  SPI-014 Drug Profile521
  tenapanor hydrochloride Drug Profile534
  TRK-390 Drug Profile571
  VS-501 Drug Profile581
Hyperphosphatemia In Chronic Kidney Disease Dormant Projects591
Hyperphosphatemia In Chronic Kidney Disease Discontinued Products601
Hyperphosphatemia In Chronic Kidney Disease Product Development Milestones6111
  Featured News &Press Releases611
    Sep 24, 2015: Keryx Receives European Approval for Fexeric (ferric citrate coordination complex) for the Treatment of Hyperphosphatemia in Adults With Chronic Kidney Disease611
    May 07, 2015: Phosphate Therapeutics announces positive results in the PEACH pivotal study of its novel phosphate binder (PT20) for the treatment of hyperphosphataemia621
    Mar 04, 2015: Keryx Biopharmaceuticals Announces Publication of Auryxia (ferric citrate) Analysis in Journal of the American Society of Nephrology621
    Feb 02, 2015: Ardelyx Reports Results from Phase 2b Clinical Trial Evaluating Tenapanor in Treating Hyperphosphatemia in Chronic Kidney Disease Patients on Hemodialysis631
    Jan 09, 2015: Keryx Biopharmaceuticals Turns to Veeva Commercial Cloud to Support First FDA-Approved Product Launch641
    Nov 17, 2014: Keryx Biopharmaceuticals Announces Trade Name Auryxia for Ferric Citrate651
    Nov 15, 2014: Keryx Biopharmaceuticals Announces Results From Ferric Citrate Phase 3 Long-Term Safety Extension Study651
    Oct 01, 2014: Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Ferric Citrate Covering Orally Administrable Forms661
    Apr 09, 2014: Keryx Biopharmaceuticals Announces Zerenex Phase 2 Results in Non-Dialysis Dependent Chronic Kidney Disease Selected as a Late Breaking Oral Presentation at the Upcoming National Kidney Foundation 2014 Spring Clinical Meeting671
    Apr 02, 2014: Keryx Biopharmaceuticals Announces EMA Validation of Marketing Authorization Application for Zerenex671
    Mar 10, 2014: Keryx Biopharmaceuticals Announces Submission of a Marketing Authorization Application for Zerenex to the European Medicines Agency681
    Jan 17, 2014: Keryx Biopharmaceuticals Announces Marketing Approval of Ferric Citrate in Japan681
    Oct 21, 2013: Keryx Biopharmaceuticals Announces PDUFA Goal Date for Zerenex New Drug Application691
    Oct 17, 2013: Keryx Biopharmaceuticals' Zerenex (Ferric Citrate Coordination Complex) Data Selected for Oral and Poster Presentations at the American Society of Nephrology's Kidney Week 2013691
    Oct 08, 2013: Keryx Biopharmaceuticals Announces FDA Acceptance for Filing of Zerenex New Drug Application702
Appendix722
  Methodology721
  Coverage721
  Secondary Research721
  Primary Research721
  Expert Panel Validation721
  Contact Us721
  Disclaimer731

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2016" Jun 22, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Hyperphosphatemia-In-Chronic-Kidney-Disease-Pipeline-Review-H1-2016-2088-15982>
  
APA:
Global Markets Direct - Market Research. (2016). Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2016 Jun 22, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Hyperphosphatemia-In-Chronic-Kidney-Disease-Pipeline-Review-H1-2016-2088-15982>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.